HC Wainwright Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

Replimune Group (NASDAQ:REPL - Free Report) had its price objective raised by HC Wainwright from $21.00 to $22.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms have also commented on REPL. Jefferies Financial Group raised their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $19.29.

Replimune Group Stock Performance

Shares of NASDAQ:REPL traded down $0.19 during trading on Thursday, reaching $14.10. 431,744 shares of the stock were exchanged, compared to its average volume of 790,791. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The stock has a 50-day moving average price of $12.54 and a 200-day moving average price of $11.74. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a market cap of $964.72 million, a PE ratio of -4.62 and a beta of 1.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Research analysts expect that Replimune Group will post -2.88 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company's stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC lifted its holdings in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after acquiring an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its position in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in Replimune Group in the third quarter valued at approximately $133,000. Finally, XTX Topco Ltd bought a new stake in shares of Replimune Group during the fourth quarter worth $137,000. Institutional investors own 92.53% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.